The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Tumor Immune Checkpoint Inhibitor Therapy Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Tumor Immune Checkpoint Inhibitor Therapy Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2029

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1774877

No of Pages : 100

Ask Your Query

Synopsis
The global Tumor Immune Checkpoint Inhibitor Therapy market size was valued at USD 54950 million in 2022 and is forecast to a readjusted size of USD 92090 million by 2029 with a CAGR of 7.7% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Immune checkpoint inhibitors are some monoclonal antibody drugs developed for the corresponding immune checkpoints. inhibition

This report is a detailed and comprehensive analysis for global Tumor Immune Checkpoint Inhibitor Therapy market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

  • Global Tumor Immune Checkpoint Inhibitor Therapy market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
  • Global Tumor Immune Checkpoint Inhibitor Therapy market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
  • Global Tumor Immune Checkpoint Inhibitor Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
  • Global Tumor Immune Checkpoint Inhibitor Therapy market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023.

The Primary Objectives in This Report Are:

  • To determine the size of the total market opportunity of global and key countries
  • To assess the growth potential for Tumor Immune Checkpoint Inhibitor Therapy
  • To forecast future growth in each product and end-use market
  • To assess competitive factors affecting the marketplace.

This report profiles key players in the global Tumor Immune Checkpoint Inhibitor Therapy market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG and Pfizer, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Tumor Immune Checkpoint Inhibitor Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

  • PD-1/PD-L1
  • CTLA-4

Market segment by Application

  • Hospital
  • Clinic
  • Other

Major players covered

  • AstraZeneca
  • Bristol-Myers Squibb
  • Roche Holdings AG
  • Novartis AG
  • Pfizer
  • Sanofi
  • Merck
  • Ono Pharmaceutical
  • Regeneron
  • Innovent

Market segment by region, regional analysis covers

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
  • South America (Brazil, Argentina, Colombia, and Rest of South America)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Tumor Immune Checkpoint Inhibitor Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tumor Immune Checkpoint Inhibitor Therapy, with price, sales, revenue and global market share of Tumor Immune Checkpoint Inhibitor Therapy from 2018 to 2023.
Chapter 3, the Tumor Immune Checkpoint Inhibitor Therapy competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tumor Immune Checkpoint Inhibitor Therapy breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Tumor Immune Checkpoint Inhibitor Therapy market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tumor Immune Checkpoint Inhibitor Therapy.
Chapter 14 and 15, to describe Tumor Immune Checkpoint Inhibitor Therapy sales channel, distributors, customers, research findings and conclusion.

Index

1 Market Overview
1.1 Product Overview and Scope of Tumor Immune Checkpoint Inhibitor Therapy
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Tumor Immune Checkpoint Inhibitor Therapy Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 PD-1/PD-L1
1.3.3 CTLA-4
1.4 Market Analysis by Application
1.4.1 Overview: Global Tumor Immune Checkpoint Inhibitor Therapy Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Tumor Immune Checkpoint Inhibitor Therapy Market Size & Forecast
1.5.1 Global Tumor Immune Checkpoint Inhibitor Therapy Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity (2018-2029)
1.5.3 Global Tumor Immune Checkpoint Inhibitor Therapy Average Price (2018-2029)
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Product and Services
2.1.4 AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AstraZeneca Recent Developments/Updates
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business
2.2.3 Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Product and Services
2.2.4 Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Bristol-Myers Squibb Recent Developments/Updates
2.3 Roche Holdings AG
2.3.1 Roche Holdings AG Details
2.3.2 Roche Holdings AG Major Business
2.3.3 Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Product and Services
2.3.4 Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Roche Holdings AG Recent Developments/Updates
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Product and Services
2.4.4 Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Novartis AG Recent Developments/Updates
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Tumor Immune Checkpoint Inhibitor Therapy Product and Services
2.5.4 Pfizer Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Pfizer Recent Developments/Updates
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Tumor Immune Checkpoint Inhibitor Therapy Product and Services
2.6.4 Sanofi Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Sanofi Recent Developments/Updates
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Tumor Immune Checkpoint Inhibitor Therapy Product and Services
2.7.4 Merck Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Merck Recent Developments/Updates
2.8 Ono Pharmaceutical
2.8.1 Ono Pharmaceutical Details
2.8.2 Ono Pharmaceutical Major Business
2.8.3 Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Product and Services
2.8.4 Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Ono Pharmaceutical Recent Developments/Updates
2.9 Regeneron
2.9.1 Regeneron Details
2.9.2 Regeneron Major Business
2.9.3 Regeneron Tumor Immune Checkpoint Inhibitor Therapy Product and Services
2.9.4 Regeneron Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Regeneron Recent Developments/Updates
2.10 Innovent
2.10.1 Innovent Details
2.10.2 Innovent Major Business
2.10.3 Innovent Tumor Immune Checkpoint Inhibitor Therapy Product and Services
2.10.4 Innovent Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Innovent Recent Developments/Updates
3 Competitive Environment: Tumor Immune Checkpoint Inhibitor Therapy by Manufacturer
3.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Manufacturer (2018-2023)
3.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Manufacturer (2018-2023)
3.3 Global Tumor Immune Checkpoint Inhibitor Therapy Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Tumor Immune Checkpoint Inhibitor Therapy by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Tumor Immune Checkpoint Inhibitor Therapy Manufacturer Market Share in 2022
3.4.2 Top 6 Tumor Immune Checkpoint Inhibitor Therapy Manufacturer Market Share in 2022
3.5 Tumor Immune Checkpoint Inhibitor Therapy Market: Overall Company Footprint Analysis
3.5.1 Tumor Immune Checkpoint Inhibitor Therapy Market: Region Footprint
3.5.2 Tumor Immune Checkpoint Inhibitor Therapy Market: Company Product Type Footprint
3.5.3 Tumor Immune Checkpoint Inhibitor Therapy Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Tumor Immune Checkpoint Inhibitor Therapy Market Size by Region
4.1.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Region (2018-2029)
4.1.2 Global Tumor Immune Checkpoint Inhibitor Therapy Consumption Value by Region (2018-2029)
4.1.3 Global Tumor Immune Checkpoint Inhibitor Therapy Average Price by Region (2018-2029)
4.2 North America Tumor Immune Checkpoint Inhibitor Therapy Consumption Value (2018-2029)
4.3 Europe Tumor Immune Checkpoint Inhibitor Therapy Consumption Value (2018-2029)
4.4 Asia-Pacific Tumor Immune Checkpoint Inhibitor Therapy Consumption Value (2018-2029)
4.5 South America Tumor Immune Checkpoint Inhibitor Therapy Consumption Value (2018-2029)
4.6 Middle East and Africa Tumor Immune Checkpoint Inhibitor Therapy Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Type (2018-2029)
5.2 Global Tumor Immune Checkpoint Inhibitor Therapy Consumption Value by Type (2018-2029)
5.3 Global Tumor Immune Checkpoint Inhibitor Therapy Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Application (2018-2029)
6.2 Global Tumor Immune Checkpoint Inhibitor Therapy Consumption Value by Application (2018-2029)
6.3 Global Tumor Immune Checkpoint Inhibitor Therapy Average Price by Application (2018-2029)
7 North America
7.1 North America Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Type (2018-2029)
7.2 North America Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Application (2018-2029)
7.3 North America Tumor Immune Checkpoint Inhibitor Therapy Market Size by Country
7.3.1 North America Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Country (2018-2029)
7.3.2 North America Tumor Immune Checkpoint Inhibitor Therapy Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Type (2018-2029)
8.2 Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Application (2018-2029)
8.3 Europe Tumor Immune Checkpoint Inhibitor Therapy Market Size by Country
8.3.1 Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Country (2018-2029)
8.3.2 Europe Tumor Immune Checkpoint Inhibitor Therapy Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Tumor Immune Checkpoint Inhibitor Therapy Market Size by Region
9.3.1 Asia-Pacific Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Tumor Immune Checkpoint Inhibitor Therapy Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Type (2018-2029)
10.2 South America Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Application (2018-2029)
10.3 South America Tumor Immune Checkpoint Inhibitor Therapy Market Size by Country
10.3.1 South America Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Country (2018-2029)
10.3.2 South America Tumor Immune Checkpoint Inhibitor Therapy Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Market Size by Country
11.3.1 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Tumor Immune Checkpoint Inhibitor Therapy Market Drivers
12.2 Tumor Immune Checkpoint Inhibitor Therapy Market Restraints
12.3 Tumor Immune Checkpoint Inhibitor Therapy Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Tumor Immune Checkpoint Inhibitor Therapy and Key Manufacturers
13.2 Manufacturing Costs Percentage of Tumor Immune Checkpoint Inhibitor Therapy
13.3 Tumor Immune Checkpoint Inhibitor Therapy Production Process
13.4 Tumor Immune Checkpoint Inhibitor Therapy Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Tumor Immune Checkpoint Inhibitor Therapy Typical Distributors
14.3 Tumor Immune Checkpoint Inhibitor Therapy Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Published By : GlobalInfoResearch

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock